Page last updated: 2024-10-28

lidocaine and Osteoporosis, Postmenopausal

lidocaine has been researched along with Osteoporosis, Postmenopausal in 1 studies

Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.

Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Radicioni, M1
Cremonesi, G1
Baraldi, E1
Leuratti, C1
Mariotti, F1

Trials

1 trial available for lidocaine and Osteoporosis, Postmenopausal

ArticleYear
Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients.
    International journal of clinical pharmacology and therapeutics, 2013, Volume: 51, Issue:4

    Topics: Bone Density Conservation Agents; Clodronic Acid; Cross-Over Studies; Dose-Response Relationship, Dr

2013